Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics (Nasdaq: NRIX), a clinical stage biopharmaceutical company focusing on targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2024:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA (September 5)
2. H.C. Wainwright 26th Annual Global Investment Conference in New York City (September 9)
3. Baird 2024 Global Healthcare Conference in New York City (September 10)
Key executives, including CEO Arthur T. Sands, CFO Hans van Houte, and CBO Jason Kantor, will participate in fireside chats and presentations. Most events will be webcast live and accessible through the Investors section of Nurix's website, with recordings available for 30 days after each event.
Nurix Therapeutics (Nasdaq: NRIX), un'azienda biofarmaceutica in fase clinica che si concentra su farmaci a modulazione proteica mirati per il cancro e le malattie infiammatorie, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settembre 2024:
1. Conferenza Sanitaria Wells Fargo 2024 a Boston, MA (5 settembre)
2. 26° Conferenza Annuale di Investimento Globale H.C. Wainwright a New York City (9 settembre)
3. Conferenza Sanitaria Globale Baird 2024 a New York City (10 settembre)
Alcuni dirigenti chiave, tra cui il CEO Arthur T. Sands, il CFO Hans van Houte e il CBO Jason Kantor, parteciperanno a discussioni informali e presentazioni. La maggior parte degli eventi sarà trasmessa in diretta web e accessibile attraverso la sezione Investitori del sito web di Nurix, con registrazioni disponibili per 30 giorni dopo ciascun evento.
Nurix Therapeutics (Nasdaq: NRIX), una empresa biofarmacéutica en etapa clínica que se centra en fármacos de modulación de proteínas dirigidos para el cáncer y enfermedades inflamatorias, ha anunciado su participación en tres conferencias de inversores en septiembre de 2024:
1. Conferencia de Salud Wells Fargo 2024 en Boston, MA (5 de septiembre)
2. 26ª Conferencia Anual de Inversión Global H.C. Wainwright en Nueva York (9 de septiembre)
3. Conferencia Global de Salud Baird 2024 en Nueva York (10 de septiembre)
Ejecutivos clave, incluido el CEO Arthur T. Sands, el CFO Hans van Houte y el CBO Jason Kantor, participarán en charlas informales y presentaciones. La mayoría de los eventos se transmitirán en vivo y serán accesibles a través de la sección de Inversores del sitio web de Nurix, con grabaciones disponibles durante 30 días después de cada evento.
Nurix Therapeutics (Nasdaq: NRIX)는 암 및 염증 질환을 위한 표적 단백질 조절 약물에 초점을 맞춘 임상 단계의 생명공학 회사로, 2024년 9월에 열리는 세 가지 투자자 컨퍼런스에 참여할 것이라고 발표했습니다:
1. 2024 웰스 파고 헬스케어 컨퍼런스 (9월 5일, 보스턴, MA)
2. H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스 (9월 9일, 뉴욕)
3. 베어드 2024 글로벌 헬스케어 컨퍼런스 (9월 10일, 뉴욕)
CEO 아서 T. 샌즈, CFO 한스 반 하우트, CBO 제이슨 칸토르를 포함한 주요 경영진이 대화 및 발표에 참여할 예정입니다. 대부분의 이벤트는 생중계되며 Nurix 웹사이트의 투자자 섹션을 통해 액세스할 수 있으며, 각 이벤트 후 30일 동안 녹화본이 제공됩니다.
Nurix Therapeutics (Nasdaq: NRIX), une entreprise bio-pharmaceutique en phase clinique axée sur les médicaments de modulation protéique ciblée pour le cancer et les maladies inflammatoires, a annoncé sa participation à trois prochaines conférences pour investisseurs en septembre 2024 :
1. Conférence Healthcare Wells Fargo 2024 à Boston, MA (5 septembre)
2. 26ème Conférence Annuelle d'Investissement Global H.C. Wainwright à New York (9 septembre)
3. Conférence Globale de Santé Baird 2024 à New York (10 septembre)
Des dirigeants clés, y compris le CEO Arthur T. Sands, le CFO Hans van Houte et le CBO Jason Kantor, participeront à des discussions informelles et des présentations. La majorité des événements sera diffusée en direct et accessible via la section Investisseurs du site de Nurix, avec des enregistrements disponibles pendant 30 jours après chaque événement.
Nurix Therapeutics (Nasdaq: NRIX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Proteinmodulationsmedikamente für Krebs und entzündliche Erkrankungen konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2024 angekündigt:
1. Wells Fargo Healthcare Conference 2024 in Boston, MA (5. September)
2. 26. Jahreskonferenz für globale Investitionen von H.C. Wainwright in New York City (9. September)
3. Baird 2024 Globale Gesundheitskonferenz in New York City (10. September)
Wichtige Führungskräfte, darunter CEO Arthur T. Sands, CFO Hans van Houte und CBO Jason Kantor, werden an informellen Gesprächen und Präsentationen teilnehmen. Die meisten Veranstaltungen werden live im Internet übertragen und sind über den Investorenbereich der Nurix-Website zugänglich, mit Aufzeichnungen, die 30 Tage nach jeder Veranstaltung verfügbar sind.
- None.
- None.
SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in September:
- 2024 Wells Fargo Healthcare Conference (Boston, MA)
Fireside chat: Thursday, September 5, 2024, from 4:30 – 5:05 p.m. ET - H.C. Wainwright 26th Annual Global Investment Conference (New York City)
Fireside chat: Monday, September 9, 2024, from 9:30 – 10:00 a.m. ET - Baird 2024 Global Healthcare conf (New York City) (will not be webcast)
Presentation: Tuesday, September 10, 2024, from 9:50 – 10:20 a.m. ET
Unless otherwise specified, fireside chats will be webcast live and may be accessed via links in the Investors section of the Nurix website under Events and Presentations. The archived webcasts will be available on the Nurix website for 30 days after the event.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What investor conferences will Nurix Therapeutics (NRIX) attend in September 2024?
Who will represent Nurix Therapeutics (NRIX) at the upcoming investor conferences?
Will Nurix Therapeutics' (NRIX) conference presentations be available for viewing online?
What is the focus of Nurix Therapeutics' (NRIX) drug development?
